{"groups":[{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"FG000","title":"Main Cohort"},{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 68 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"FG001","title":"Safety Expansion Cohort"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"5"}],"type":"Adverse event- not related to progression"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"2"}],"type":"Adverse event- related to progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"COVID-19 logistical restrictions"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Investigator request"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"7"}],"type":"Progressive disease- Richter's"},{"reasons":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"17"}],"type":"Progressive disease per protocol"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Stem cell transplant"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"Withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"15"}],"type":"Other, not specified"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"107"},{"groupId":"FG001","numSubjects":"51"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"107"},{"groupId":"FG001","numSubjects":"51"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All treated participants: all participants who received at least one dose of ABT-199 in either the Main Cohort or Safety Expansion Cohort"}